Key Takeaways
- Ricoh USA has sold its 3D for Healthcare division to Gary Turner, former VP and GM of Additive Manufacturing at Ricoh USA
- The division has been rebranded as Myrava and will continue to focus on patient-specific anatomical models and point-of-care services
- Myrava has a strong foundation in FDA compliance and research partnerships, including a Center of Excellence at North Carolina State University
- The medical industry remains a significant market segment for additive manufacturing, with a high demand for patient-specific solutions
Introduction to Myrava
Myrava, formerly Ricoh 3D for Healthcare, is a company that specializes in patient-specific anatomical models and point-of-care services. With its new ownership under Gary Turner, the company is poised to continue its growth and innovation in the medical industry.
Background on Ricoh 3D for Healthcare
Ricoh 3D for Healthcare was spun off from Ricoh USA in 2023, with a focus on developing patient-specific anatomical models for the medical industry. Under Turner's leadership, the company amassed a diverse range of FDA clearances and established partnerships with research institutions, including a Center of Excellence at North Carolina State University.
Comparison of Myrava and Other Medical 3D Printing Companies
| Company | Focus | FDA Clearances | Research Partnerships |
|---|---|---|---|
| Myrava | Patient-specific anatomical models, point-of-care services | 10+ FDA clearances | North Carolina State University, other research institutions |
| Other Medical 3D Printing Companies | Varied, including implants, surgical guides, and prosthetics | Varies | Varies |
Market Outlook for Medical 3D Printing
The medical industry remains a significant market segment for additive manufacturing, with a high demand for patient-specific solutions. The US is a major hub for medical innovation, with a large and growing market for 3D printed medical devices. According to industry reports, the global medical 3D printing market is expected to reach $3.4 billion by 2027, growing at a CAGR of 17.4% from 2020 to 2027.
Conclusion
Myrava, with its strong foundation in FDA compliance, research partnerships, and point-of-care services, is well-positioned to capitalize on the growing demand for patient-specific medical solutions. As the medical 3D printing market continues to grow, Myrava is likely to remain a major player in the industry.
Bottom Line
The sale of Ricoh 3D for Healthcare to Gary Turner and its rebranding as Myrava marks a significant development in the medical 3D printing industry. With its focus on patient-specific anatomical models and point-of-care services, Myrava is poised to drive innovation and growth in the medical industry, and its strong foundation in FDA compliance and research partnerships will support its continued success.